Rapid Acting Insulin Market Size Worth $11.4 billion by 2027 - KBV Research


Posted May 21, 2021 by kbv_research

The Global Rapid Acting Insulin Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 5.6% CAGR during the forecast period.
 
According to a new report Global Rapid Acting Insulin Market, published by KBV research, The Global Rapid Acting Insulin Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 5.6% CAGR during the forecast period.
The Insulin Lispro market dominated the Global Rapid Acting Insulin Market by Product Type in 2020, and would continue to be a dominant market till 2027. The Insulin Aspart market is expected to witness a CAGR of 5.9% during (2021 - 2027).

The Drug Stores & Retail Pharmacies market dominated the Global Rapid Acting Insulin Market by Distribution Channel in 2020, growing at a CAGR of 5.2 % during the forecast period. The Hospital Pharmacies market is experiencing a CAGR of 5.9% during (2021 - 2027). The Online Providers market is expected to witness a CAGR of 6.5% during (2021 - 2027).

The North America market dominated the Global Rapid Acting Insulin Market by Region in 2020. On the other hand, Asia-Pacific would exhibit a prominent growth rate in the global rapid-acting insulin market, due to the adoption of modern & western lifestyle behaviors and the growing occurrences of obesity. This would create many growth avenues for the global rapid-acting insulin market during the forecast period.

Full Report: https://www.kbvresearch.com/rapid-acting-insulin-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.

Global Rapid Acting Insulin Market Segmentation

By Product Type
• Insulin Lispro
• Insulin Aspart
• Insulin Glulisine

By Indication
• Type 2 Diabetes
• Type 1 Diabetes

By Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Geography

North America
• US
• Canada
• Mexico
• Rest of North America

Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled
• Merck & Co., Inc.
• Sanofi S.A.
• Novo Nordisk A/S
• Eli Lilly and Company
• Adocia SA
• Biocon Limited
• Gan & Lee Pharmaceuticals
• Geropharm LLC
• Wockhardt Ltd.
• MannKind Corporation
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By KBV Research
Phone +1 (646) 661-6066
Business Address 244 Fifth Avenue, Suite 1407 USA
N.Y. 10001 United States (U.S)
Country United States
Categories Health
Tags rapid acting insulin market analysis report , rapid acting insulin market forecast , rapid acting insulin market growth , rapid acting insulin market trends
Last Updated May 21, 2021